<div class="floatDisplay"><div class="table-wrap" id="tbl1">
<table>
<caption tabindex="0">
<span class="label">Table 1</span><span>Contribution
 of ACT total score ≥20 and improvement from baseline ≥3 to the 
composite primary effectiveness endpoint in SLS Asthma (Week 24 data; 
PEA population).</span>
</caption>
<tbody>
<tr>
<th scope="col" rowspan="2">Patients, n/N (%)<a href="#title-footnote-tbl1fna" id="back-title-footnote-tbl1fna" class="figureLink"><sup>a</sup></a><span class="crossref-label" style="display: none;"></span>
</th>
<th scope="col" colspan="3">Overall PEA population</th>
<th scope="col" colspan="3">ICS subset</th>
<th scope="col" colspan="3">ICS/LABA subset</th>
</tr>
<tr>
<th scope="col">FF/VI (n = 1512)</th>
<th scope="col">UC (n = 1514)</th>
<th scope="col">Adjusted OR (95% CI)<a href="#title-footnote-tbl1fnb" id="back-title-footnote-tbl1fnb" class="figureLink"><sup>b</sup></a><span class="crossref-label" style="display: none;"></span>
</th>
<th scope="col">FF/VI (n = 484)</th>
<th scope="col">UC (n = 492)</th>
<th scope="col">Adjusted OR (95% CI)<a href="#title-footnote-tbl1fnc" id="back-title-footnote-tbl1fnc" class="figureLink"><sup>c</sup></a><span class="crossref-label" style="display: none;"></span>
</th>
<th scope="col">FF/VI (n = 997)</th>
<th scope="col">UC (n = 989)</th>
<th scope="col">Adjusted OR (95% CI)<a href="#title-footnote-tbl1fnc" id="back-title-footnote-tbl1fnc" class="figureLink"><sup>c</sup></a><span class="crossref-label" style="display: none;"></span>
</th>
</tr>
<tr>
<td>ACT total score ≥ 20 and/or improvement from baseline ≥ 3<br><br>(composite endpoint)</td>
<td>977/1373 (71)</td>
<td>784/1399 (56)</td>
<td>2.00 (1.70–2.34)</td>
<td>324/440 (74)</td>
<td>259/454 (57)</td>
<td>2.13 (1.60–2.83)</td>
<td>637/908 (70)</td>
<td>511/916 (56)</td>
<td>1.95 (1.60–2.38)</td>
</tr>
<tr>
<td>ACT total score ≥ 20</td>
<td>704/1373 (51)</td>
<td>501/1399 (36)</td>
<td>1.98 (1.69–2.33)</td>
<td>257/440 (58)</td>
<td>183/454 (40)</td>
<td>2.34 (1.77–3.11)</td>
<td>432/908 (48)</td>
<td>308/916 (34)</td>
<td>1.84 (1.51–2.24)</td>
</tr>
<tr>
<td>Improvement from baseline ≥ 3</td>
<td>927/1373 (68)</td>
<td>724/1399 (52)</td>
<td>2.05 (1.75–2.40)</td>
<td>304/440 (69)</td>
<td>234/454 (52)</td>
<td>2.15 (1.62–2.84)</td>
<td>607/908 (67)</td>
<td>476/916 (52)</td>
<td>2.01 (1.66–2.45)</td>
</tr>
</tbody>
</table>
<a href="javascript:void(0)" class="tableLink" onclick="window.open('/action/showFullTableImage?isHtml=true&amp;tableId=tbl1&amp;pii=S095461111830194X', '_blank')">
                        View Table in HTML
                    </a><div class="footnote"><p>Abbreviations: ACT, 
Asthma Control Test; CI, confidence interval; FF/VI, fluticasone 
furoate/vilanterol; ICS, inhaled corticosteroid; LABA, long-acting beta<sub>2</sub>-agonist; OR, odds ratio; PEA, primary effectiveness analysis; SLS, Salford Lung Study; UC, usual care.</p></div>
<div class="footnote" id="tbl1fna">
<a href="#back-tbl1fna">a</a>Percentages based on a denominator of the number of patients evaluable for ACT.</div>
<div class="footnote" id="tbl1fnb">
<a href="#back-tbl1fnb">b</a>ORs
 and 95% CIs for the difference between FF/VI and UC were determined 
using a logistic regression model adjusted for randomized treatment, 
baseline ACT total score, baseline ACT total score squared (composite 
endpoint only), asthma maintenance therapy at baseline per randomization
 stratification, age, and gender.</div>
<div class="footnote" id="tbl1fnc">
<a href="#back-tbl1fnc">c</a>For
 analysis of the ICS and ICS/LABA subsets of the PEA population, the 
statistical models did not include the asthma maintenance therapy at 
baseline per randomization stratification variable.</div>
</div></div>